First Horizon Advisors, Inc. Halozyme Therapeutics, Inc. Transaction History

First Horizon Advisors, Inc.

$3.81 Billion
Q2 2025

A detailed history of First Horizon Advisors, Inc. transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, First Horizon Advisors, Inc. holds 677 shares of HALO stock, worth $42,041. This represents 0.0% of its overall portfolio holdings.

Number of Shares

677

Previous 1,090 37.89%

Holding current value

$42,041

Previous $69,000 49.28%

% of portfolio

0.0%

Previous 0.0%

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 05, 2025	SELL	$47.91 - $70.14 $19,786 - $28,967	-413 Reduced 37.89%	677 $35,000
Q1 2025 Apr 28, 2025	SELL	$47.74 - $65.16 $1,384 - $1,889	-29 Reduced 2.59%	1,090 $69,000
Q4 2024 Feb 03, 2025	SELL	$42.57 - $61.09 $7,279 - $10,446	-171 Reduced 13.26%	1,119 $53,000
Q3 2024 Nov 08, 2024	BUY	$51.3 - $64.42 $1,590 - $1,997	31 Added 2.46%	1,290 $73,000
Q2 2024 Jul 19, 2024	SELL	$37.81 - $52.4 $7,032 - $9,746	-186 Reduced 12.87%	1,259 $65,000
Q1 2024 Apr 26, 2024	SELL	$33.68 - $41.95 $1,549 - $1,929	-46 Reduced 3.09%	1,445 $58,000
Q4 2023 Feb 06, 2024	BUY	$33.32 - $42.1 $9,762 - $12,335	293 Added 24.46%	1,491 $55,000
Q3 2023 Oct 27, 2023	BUY	$36.46 - $44.03 $5,067 - $6,120	139 Added 13.13%	1,198 $45,000
Q2 2023 Aug 03, 2023	BUY	$30.28 - $38.74 $8,478 - $10,847	280 Added 35.94%	1,059 $38,000
Q1 2023 May 15, 2023	BUY	$32.86 - $55.7 $4,600 - $7,798	140 Added 21.91%	779 $29,000
Q4 2022 Feb 10, 2023	SELL	$40.06 - $59.44 $3,164 - $4,695	-79 Reduced 11.0%	639 $36,000
Q3 2022 Nov 09, 2022	SELL	$38.53 - $51.78 $154 - $207	-4 Reduced 0.55%	718 $28,000
Q2 2022 Aug 02, 2022	BUY	$37.35 - $48.3 $17,629 - $22,797	472 Added 188.8%	722 $31,000
Q1 2022 May 10, 2022	SELL	$31.97 - $41.06 $13,203 - $16,957	-413 Reduced 62.29%	250 $10,000
Q4 2021 Feb 09, 2022	SELL	$31.82 - $40.75 $20,778 - $26,609	-653 Reduced 49.62%	663 $26,000
Q3 2021 Nov 15, 2021	BUY	$38.47 - $46.42 $18,234 - $22,003	474 Added 56.29%	1,316 $53,000
Q3 2021 Nov 09, 2021	SELL	$38.47 - $46.42 $14,233 - $17,175	-370 Reduced 30.53%	842 $34,000
Q2 2021 Aug 09, 2021	SELL	$38.84 - $51.31 $7,418 - $9,800	-191 Reduced 13.61%	1,212 $55,000
Q1 2021 May 11, 2021	BUY	$39.51 - $51.45 $22,402 - $29,172	567 Added 67.82%	1,403 $58,000
Q4 2020 Feb 11, 2021	BUY	$25.81 - $43.62 $13,601 - $22,987	527 Added 170.55%	836 $35,000
Q3 2020 Nov 12, 2020	BUY	$25.74 - $29.63 $3,166 - $3,644	123 Added 66.13%	309 $8,000
Q2 2020 Jul 31, 2020	BUY	$16.25 - $26.81 $3,022 - $4,986	186 New	186 $4,000

Others Institutions Holding HALO

# of Institutions

581

Shares Held

123M

Call Options Held

308K

Put Options Held

186K

View Full List

About HALOZYME THERAPEUTICS, INC.

Ticker HALO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 139,288,992
Market Cap $8.65B
Description
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...

More about HALO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of First Horizon Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on First Horizon Advisors, Inc. with notifications on news.

Account

First Horizon Advisors, Inc. Halozyme Therapeutics, Inc. Transaction History